StudyID,Drug_Name,No_Arm,Randomization,Central_Random,Rand_Ratio,Random_Parallel,Random_Crossover,Random_Fact,Random_Cluster,Stratification,No_Stratification,Single_Arm,Hist_control,Blinding,Level_Blinding,Placebo_control,Active_Control,Control_Drug,Obj_Primary,No_Prim_EP,Primary_EP,Success_Criteria_Text,Primary_EP_SC,Key_Second_EP,Key_Second_EP_SC,IRC,Sample_Size,Power,Alpha,Sided,Subgroup,Interim,Timing_IA,Alpha_Spend_Func,Adaptive_Design,Consistency_Sens_Ana_PE,Consistency_Sens_Ana_SE,Post_Hoc_Ana,Intercurrent_Events,Gatekeeping_Strategy,Reg_Alignment,Fast_Track,Breakthrough,Priority_Review,Accelerated_App,Orphan_Drug,Pediatric,Rare_Disease,Reg_Audit,Consistency_MRCT
NCT00387465,Azacitidine 30mg/m2; Entinostat; Azacitidine 40mg/m2,3,Yes,,,No,No,No,,,,No,No,No,0,No,No,,,2,(Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT); (Phase II) Objective Response Rate After Treatment With Azacitidine and Entinostat as Assessed by Number of Participants With Response After at Least One Cycle of Therapy,,,Effect of Entinostat and Azacitidine on DNA Methylation and Response,,,,,,,,,,,,,,,,,,,,,,,,,,
